Skip to main content

Table 2 Data used in network meta-analysis

From: The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

Study

Dasatinib

Nilotinib 600 mg

Nilotinib 800 mg

Imatinib 400 mg

Imatinib 800 mg

Complete cytogenic response

6 months

     

DASISION

73.0%

  

59.2%

 

ENESTed

 

67.0%

63.0%

44.9%

 

Baccarani et al.

   

50.0%

51.9%

German CML Study IV

   

21.5%

33.5%

Cortes et al. 2010

   

44.6%

56.7%

ISTAHIT

   

19.8%

43.8%

SPIRIT

   

50.0%

69.0%

12 months

     

DASISION study group

83.4%

  

71.5%

 

ENESTed study group

 

80.1%

77.9%

65.0%

 

Baccarani et al. (2009)

   

58.3%

63.9%

German CML Study IV

   

49.8%

63.2%

Cortes et al. 2010

   

65.6%

69.9%

S0325 Intergroup Trial

82.0%

  

69.0%

 

SPIRIT

   

58.0%

65.0%

18 months

     

Dasatinib Study Group

88.6%

    

DASISION study group

78.0%

  

70.0%

 

ENESTed study group

 

85.0%

82.0%

74.0%

 

German CML Study IV

   

66.6%

73.8%

Major Molecular response

12 months

     

Bacarrani et al. (2009)

   

33.3%

39.8%

DASISION study group

45.9%

  

28.1%

 

ENESTed Study group

 

44.0%

43.1%

21.9%

 

German CML Study IV

   

30.8%

54.8%

Cortes et al. 2010

   

40.1%

46.4%

SPIRIT

   

38.0%

49.0%

S0325 Intergroup Trial

59.0%

  

43.0%

Â